Identification
NameEstrone sulfate
Accession NumberDB04574
TypeSmall Molecule
GroupsApproved
Description

Estrone sulfate (as estropipate) is a form of estrogen. It has several uses such as: alleviate symptoms of menopause as hormone replacement therapy, treatment some types of infertility, treatment of some conditions leading to underdevelopment of female sexual characteristics, treatment of vaginal atrophy, treatment of some types of breast cancer (particularly in men and postmenopausal women), treatment of prostate cancer and prevention of osteoporosis.

Structure
Thumb
Synonyms
Estra-1,3,5 (10)-triene-17-one-3-yl-sulfate
Estrone 3-sulfate
Estrone bisulfate
Estrone hemisulfate
Estrone hydrogen sulfate
estrone sulphate
Estrone-3-sulphate
Estrone, hydrogen sulfate
External IDs US-2917522
Product Ingredients
IngredientUNIICASInChI KeyDetails
Estrone sodium sulfate6K6FDA543A 438-67-5VUCAHVBMSFIGAI-ZFINNJDLSA-MDetails
EstropipateSVI38UY019 7280-37-7HZEQBCVBILBTEP-ZFINNJDLSA-NDetails
Potassium estrone sulfateC354LET0O4 1240-04-6CUQHOFAEIPGLBH-ZFINNJDLSA-MDetails
Product Images
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ogen .625Tablet0.75 mgOralPfizer1994-12-312012-08-24Canada
Ogen 1.25Tablet1.5 mgOralPfizer1994-12-312012-08-24Canada
Ogen 2.5Tablet3.0 mgOralPfizer1994-12-312012-08-24Canada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
EstropipateTablet.75 mg/1OralPhysicians Total Care, Inc.2003-03-21Not applicableUs
EstropipateTablet.75 mg/1OralActavis Pharma Company1993-09-23Not applicableUs
EstropipateTablet.75 mg/1OralAvera Mc Kennan Hospital2016-02-05Not applicableUs
EstropipateTablet1.5 mg/1OralPhysicians Total Care, Inc.2003-03-21Not applicableUs
EstropipateTablet1.5 mg/1OralActavis Pharma Company1993-09-23Not applicableUs
EstropipateTablet1.5 mg/1OralAvera Mc Kennan Hospital2015-07-07Not applicableUs
EstropipateTablet3 mg/1OralPhysicians Total Care, Inc.2003-03-26Not applicableUs
EstropipateTablet3 mg/1OralActavis Pharma Company1993-09-23Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
OgenNot Available
ORTHO-ESTNot Available
Brand mixtures
NameLabellerIngredients
Esterified Estrogens and MethyltestosteroneTal Pharma Llc
Categories
UNIIQTL48N278K
CAS number481-97-0
WeightAverage: 350.429
Monoisotopic: 350.118794504
Chemical FormulaC18H22O5S
InChI KeyJKKFKPJIXZFSSB-CBZIJGRNSA-N
InChI
InChI=1S/C18H22O5S/c1-18-9-8-14-13-5-3-12(23-24(20,21)22)10-11(13)2-4-15(14)16(18)6-7-17(18)19/h3,5,10,14-16H,2,4,6-9H2,1H3,(H,20,21,22)/t14-,15-,16+,18+/m1/s1
IUPAC Name
[(1S,10R,11S,15S)-15-methyl-14-oxotetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-2(7),3,5-trien-5-yl]oxidanesulfonic acid
SMILES
C[C@]12CC[[email protected]]3[C@@H](CCC4=C3C=CC(OS(O)(=O)=O)=C4)[C@@H]1CCC2=O
Pharmacology
Indication

Estropipate is used for the treatment of moderate to severe vasomotor symptoms associated with the monopause, and moderate to severe symptoms of vulval and vaginal atrophy associated with the menopause. It is also used to treat hypoestrogenism due to hypogonadism, castration or primary ovarian failure, and prevent postmenopausal osteoporosis.

Structured Indications
Pharmacodynamics

Estropipate is an estrogenic substance. It acts as naturally produced estrogen does. Estrogens act through binding to nuclear receptors in estrogen-responsive tissues. Circulating estrogens modulate the pituitary secretion of the gonadotropins, luteinizing hormone (LH) and follicle stimulating hormone (FSH), through a negative feedback mechanism. Estrogens act to reduce the elevated levels of these hormones seen in postmenopausal women.

Mechanism of action

Estradiol enters target cells freely (e.g., female organs, breasts, hypothalamus, pituitary) and interacts with a target cell receptor. When the estrogen receptor has bound its ligand it can enter the nucleus of the target cell, and regulate gene transcription which leads to formation of messenger RNA. The mRNA interacts with ribosomes to produce specific proteins that express the effect of estradiol upon the target cell. Estrogens increase the hepatic synthesis of sex hormone binding globulin (SHBG), thyroid-binding globulin (TBG), and other serum proteins and suppress follicle-stimulating hormone (FSH) from the anterior pituitary.

TargetKindPharmacological actionActionsOrganismUniProt ID
Estrogen receptor alphaProteinyes
agonist
HumanP03372 details
Estrogen receptor betaProteinunknown
agonist
HumanQ92731 details
Related Articles
Absorption

Estropipate is well absorbed through the skin and gastrointestinal tract. When applied for a local action, absorption is usually sufficient to cause systemic effects.

Volume of distributionNot Available
Protein bindingNot Available
Metabolism

Exogenous estrogens are metabolized in the same manner as endogenous estrogens. Circulating estrogens exist in a dynamic equilibrium of metabolic interconversions. These transformations take place mainly in the liver. Estradiol is converted reversibly to estrone, and both can be converted to estriol, which is the major urinary metabolite. Estrogens also undergo enterohepatic recirculation via sulfate and glucuronide conjugation in the liver, biliary secretion of conjugates into the intestine, and hydrolysis in the gut followed by reabsorption. In postmenopausal women, a significant proportion of the circulating estrogens exist as sulfate conjugates, especially estrone sulfate, which serves as a circulating reservoir for the formation of more active estrogens.

SubstrateEnzymesProduct
Estrone sulfate
Not Available
EstroneDetails
Estrone sulfate
Not Available
EstriolDetails
Route of elimination

Estradiol, estrone and estriol are excreted in the urine along with glucuronide and sulfate conjugates

Half lifeNot Available
ClearanceNot Available
ToxicityNot Available
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
17-Beta Hydroxysteroid Dehydrogenase III DeficiencyDiseaseSMP00356
Androgen and Estrogen MetabolismMetabolicSMP00068
Sulfate/Sulfite MetabolismMetabolicSMP00041
Sulfite oxidase deficiencyDiseaseSMP00532
Aromatase deficiencyDiseaseSMP00565
Pharmacogenomic Effects/ADRs Not Available
Interactions
Drug Interactions
DrugInteractionDrug group
1,10-PhenanthrolineThe serum concentration of Estrone sulfate can be decreased when it is combined with 1,10-Phenanthroline.Experimental
2,4-thiazolidinedioneThe therapeutic efficacy of Thiazolidinedione can be decreased when used in combination with Estrone sulfate.Investigational
3,4-DichloroisocoumarinThe serum concentration of Estrone sulfate can be decreased when it is combined with 3,4-Dichloroisocoumarin.Experimental
4-(2-Aminoethyl)Benzenesulfonyl FluorideThe serum concentration of Estrone sulfate can be decreased when it is combined with 4-(2-AMINOETHYL)BENZENESULFONYL FLUORIDE.Experimental
AbirateroneThe serum concentration of Estrone sulfate can be increased when it is combined with Abiraterone.Approved
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Estrone sulfate.Approved, Investigational
AceclofenacThe risk or severity of adverse effects can be increased when Aceclofenac is combined with Estrone sulfate.Approved
AcenocoumarolEstrone sulfate may decrease the anticoagulant activities of Acenocoumarol.Approved
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Estrone sulfate.Withdrawn
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Estrone sulfate.Approved, Vet Approved
AcitretinThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Acitretin.Approved
AdapaleneThe risk or severity of adverse effects can be increased when Adapalene is combined with Estrone sulfate.Approved
AICA ribonucleotideThe therapeutic efficacy of Aicar can be decreased when used in combination with Estrone sulfate.Experimental
AldesleukinEstrone sulfate may decrease the antineoplastic activities of Aldesleukin.Approved
AlitretinoinThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Alitretinoin.Approved, Investigational
AlogliptinThe serum concentration of Estrone sulfate can be decreased when it is combined with Alogliptin.Approved
Alpha-1-proteinase inhibitorThe serum concentration of Estrone sulfate can be decreased when it is combined with Alpha-1-proteinase inhibitor.Approved
Aluminum hydroxideThe bioavailability of Estrone sulfate can be decreased when combined with Aluminum hydroxide.Approved
AmbenoniumThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Ambenonium.Approved
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Estrone sulfate.Approved
AmiodaroneThe metabolism of Estrone sulfate can be decreased when combined with Amiodarone.Approved, Investigational
AmobarbitalThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Amobarbital.Approved, Illicit
Amphotericin BEstrone sulfate may increase the hypokalemic activities of Amphotericin B.Approved, Investigational
AmprenavirThe serum concentration of Estrone sulfate can be decreased when it is combined with Amprenavir.Approved
AndrographolideThe risk or severity of adverse effects can be increased when HMPL-004 is combined with Estrone sulfate.Investigational
AnisodamineThe risk or severity of adverse effects can be increased when Anisodamine is combined with Estrone sulfate.Investigational
AntipyrineThe risk or severity of adverse effects can be increased when Antipyrine is combined with Estrone sulfate.Approved
Antithrombin III humanThe serum concentration of Estrone sulfate can be decreased when it is combined with Antithrombin III human.Approved
ApixabanThe serum concentration of Estrone sulfate can be decreased when it is combined with Apixaban.Approved
ApocyninThe risk or severity of adverse effects can be increased when Acetovanillone is combined with Estrone sulfate.Investigational
ApremilastThe risk or severity of adverse effects can be increased when Apremilast is combined with Estrone sulfate.Approved, Investigational
AprepitantThe serum concentration of Estrone sulfate can be increased when it is combined with Aprepitant.Approved, Investigational
AprotininThe serum concentration of Estrone sulfate can be decreased when it is combined with Aprotinin.Approved, Withdrawn
ArgatrobanThe serum concentration of Estrone sulfate can be decreased when it is combined with Argatroban.Approved, Investigational
ArmodafinilThe serum concentration of Estrone sulfate can be decreased when it is combined with Armodafinil.Approved, Investigational
ArtemetherThe serum concentration of Estrone sulfate can be decreased when it is combined with Artemether.Approved
AtazanavirThe metabolism of Estrone sulfate can be decreased when combined with Atazanavir.Approved, Investigational
AtomoxetineThe metabolism of Estrone sulfate can be decreased when combined with Atomoxetine.Approved
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Estrone sulfate.Approved
AzapropazoneThe risk or severity of adverse effects can be increased when Azapropazone is combined with Estrone sulfate.Withdrawn
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Estrone sulfate.Approved
AzithromycinThe metabolism of Estrone sulfate can be decreased when combined with Azithromycin.Approved
BalaglitazoneThe therapeutic efficacy of Balaglitazone can be decreased when used in combination with Estrone sulfate.Investigational
BalsalazideThe risk or severity of adverse effects can be increased when Balsalazide is combined with Estrone sulfate.Approved, Investigational
BarbexacloneThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Barbexaclone.Experimental
BarbitalThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Barbital.Illicit
BatimastatThe serum concentration of Estrone sulfate can be decreased when it is combined with Batimastat.Experimental
BazedoxifeneThe serum concentration of Estrone sulfate can be increased when it is combined with Bazedoxifene.Approved, Investigational
BenazeprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Benazepril.Approved, Investigational
BendroflumethiazideEstrone sulfate may increase the hypokalemic activities of Bendroflumethiazide.Approved
BenoxaprofenThe risk or severity of adverse effects can be increased when Benoxaprofen is combined with Estrone sulfate.Withdrawn
BenzamidineThe serum concentration of Estrone sulfate can be decreased when it is combined with Benzamidine.Experimental
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Estrone sulfate.Approved
Betulinic AcidThe risk or severity of adverse effects can be increased when Betulinic Acid is combined with Estrone sulfate.Investigational
BexaroteneThe serum concentration of Estrone sulfate can be decreased when it is combined with Bexarotene.Approved, Investigational
Bismuth SubcitrateThe bioavailability of Estrone sulfate can be decreased when combined with Bismuth Subcitrate.Approved
BivalirudinThe serum concentration of Estrone sulfate can be decreased when it is combined with Bivalirudin.Approved, Investigational
BoceprevirThe serum concentration of Estrone sulfate can be decreased when it is combined with Boceprevir.Withdrawn
BortezomibThe metabolism of Estrone sulfate can be decreased when combined with Bortezomib.Approved, Investigational
BosentanThe serum concentration of Estrone sulfate can be decreased when it is combined with Bosentan.Approved, Investigational
BromfenacThe risk or severity of adverse effects can be increased when Bromfenac is combined with Estrone sulfate.Approved
BucillamineThe risk or severity of adverse effects can be increased when Bucillamine is combined with Estrone sulfate.Investigational
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Estrone sulfate.Withdrawn
BumetanideEstrone sulfate may increase the hypokalemic activities of Bumetanide.Approved
CaffeineThe metabolism of Estrone sulfate can be decreased when combined with Caffeine.Approved
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Estrone sulfate.Approved, Nutraceutical
Calcium CarbonateThe bioavailability of Estrone sulfate can be decreased when combined with Calcium carbonate.Approved
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Estrone sulfate.Approved
CandoxatrilThe serum concentration of Estrone sulfate can be decreased when it is combined with Candoxatril.Experimental
CandoxatrilatThe serum concentration of Estrone sulfate can be decreased when it is combined with Candoxatrilat.Experimental
CaptoprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Captopril.Approved
CarbamazepineThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Carbamazepine.Approved, Investigational
CarprofenThe risk or severity of adverse effects can be increased when Carprofen is combined with Estrone sulfate.Approved, Vet Approved, Withdrawn
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Estrone sulfate.Experimental
CelecoxibThe risk or severity of adverse effects can be increased when Celecoxib is combined with Estrone sulfate.Approved, Investigational
CeritinibThe serum concentration of Estrone sulfate can be increased when it is combined with Ceritinib.Approved
ChloroquineThe risk or severity of adverse effects can be increased when Chloroquine is combined with Estrone sulfate.Approved, Vet Approved
ChlorothiazideEstrone sulfate may increase the hypokalemic activities of Chlorothiazide.Approved, Vet Approved
ChlorotrianiseneThe serum concentration of Estrone sulfate can be increased when it is combined with Chlorotrianisene.Withdrawn
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Estrone sulfate.Approved
ChlorthalidoneEstrone sulfate may increase the hypokalemic activities of Chlorthalidone.Approved
CholestyramineThe serum concentration of Estrone sulfate can be decreased when it is combined with Cholestyramine.Approved
Choline magnesium trisalicylateThe risk or severity of adverse effects can be increased when Trisalicylate-choline is combined with Estrone sulfate.Approved
ChymostatinThe serum concentration of Estrone sulfate can be decreased when it is combined with Chymostatin.Experimental
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Estrone sulfate.Experimental
CilastatinThe serum concentration of Estrone sulfate can be decreased when it is combined with Cilastatin.Approved
CilazaprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Cilazapril.Approved
CinoxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Cinoxacin.Approved, Withdrawn
CiprofloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Ciprofloxacin.Approved, Investigational
CitalopramThe metabolism of Estrone sulfate can be decreased when combined with Citalopram.Approved
ClarithromycinThe metabolism of Estrone sulfate can be decreased when combined with Clarithromycin.Approved
ClemastineThe metabolism of Estrone sulfate can be decreased when combined with Clemastine.Approved
ClobazamThe serum concentration of Estrone sulfate can be decreased when it is combined with Clobazam.Approved, Illicit
ClonixinThe risk or severity of adverse effects can be increased when Clonixin is combined with Estrone sulfate.Approved
ClotrimazoleThe metabolism of Estrone sulfate can be decreased when combined with Clotrimazole.Approved, Vet Approved
CobicistatThe serum concentration of Estrone sulfate can be decreased when it is combined with Cobicistat.Approved
ColesevelamThe serum concentration of Estrone sulfate can be decreased when it is combined with Colesevelam.Approved
ColestipolThe serum concentration of Estrone sulfate can be decreased when it is combined with Colestipol.Approved
ConivaptanThe serum concentration of Estrone sulfate can be increased when it is combined with Conivaptan.Approved, Investigational
Conjugated estrogensThe serum concentration of Estrone sulfate can be increased when it is combined with Conjugated Equine Estrogens.Approved
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Estrone sulfate.Approved
CrizotinibThe metabolism of Estrone sulfate can be decreased when combined with Crizotinib.Approved
CurcuminThe risk or severity of adverse effects can be increased when Curcumin is combined with Estrone sulfate.Investigational
CyclosporineThe metabolism of Estrone sulfate can be decreased when combined with Cyclosporine.Approved, Investigational, Vet Approved
Cyproterone acetateThe serum concentration of Estrone sulfate can be decreased when it is combined with Cyproterone acetate.Approved, Investigational
Dabigatran etexilateThe serum concentration of Estrone sulfate can be decreased when it is combined with Dabigatran etexilate.Approved
DabrafenibThe serum concentration of Estrone sulfate can be decreased when it is combined with Dabrafenib.Approved
DarexabanThe serum concentration of Estrone sulfate can be decreased when it is combined with Ym150.Investigational
DarunavirThe metabolism of Estrone sulfate can be decreased when combined with Darunavir.Approved
DasatinibThe serum concentration of Estrone sulfate can be increased when it is combined with Dasatinib.Approved, Investigational
DecamethoniumThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Decamethonium.Approved
DeferasiroxThe serum concentration of Estrone sulfate can be decreased when it is combined with Deferasirox.Approved, Investigational
DelavirdineThe metabolism of Estrone sulfate can be decreased when combined with Delavirdine.Approved
DemecariumThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Demecarium.Approved
DeoxyspergualinThe therapeutic efficacy of Deoxyspergualin can be decreased when used in combination with Estrone sulfate.Investigational
DexamethasoneThe serum concentration of Estrone sulfate can be decreased when it is combined with Dexamethasone.Approved, Investigational, Vet Approved
DiclofenacThe risk or severity of adverse effects can be increased when Diclofenac is combined with Estrone sulfate.Approved, Vet Approved
DicoumarolEstrone sulfate may decrease the anticoagulant activities of Dicoumarol.Approved
DienestrolThe serum concentration of Estrone sulfate can be increased when it is combined with Dienestrol.Approved
DiethylstilbestrolThe serum concentration of Estrone sulfate can be increased when it is combined with Diethylstilbestrol.Approved
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Estrone sulfate.Approved
DihydroergotamineThe metabolism of Estrone sulfate can be decreased when combined with Dihydroergotamine.Approved
DihydrotestosteroneEstrone sulfate may increase the fluid retaining activities of Dihydrotestosterone.Illicit
DiltiazemThe metabolism of Estrone sulfate can be decreased when combined with Diltiazem.Approved
DonepezilThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Donepezil.Approved
DoxycyclineThe metabolism of Estrone sulfate can be decreased when combined with Doxycycline.Approved, Investigational, Vet Approved
DronedaroneThe metabolism of Estrone sulfate can be decreased when combined with Dronedarone.Approved
DroxicamThe risk or severity of adverse effects can be increased when Droxicam is combined with Estrone sulfate.Approved
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Estrone sulfate.Approved
DuvelisibThe risk or severity of adverse effects can be increased when Duvelisib is combined with Estrone sulfate.Investigational
E-6201The risk or severity of adverse effects can be increased when E6201 is combined with Estrone sulfate.Investigational
EbselenThe risk or severity of adverse effects can be increased when Ebselen is combined with Estrone sulfate.Investigational
EcabetThe serum concentration of Estrone sulfate can be decreased when it is combined with Ecabet.Approved, Investigational
EchothiophateThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Echothiophate.Approved
EdoxabanThe serum concentration of Estrone sulfate can be decreased when it is combined with Edoxaban.Approved
EdrophoniumThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Edrophonium.Approved
EfavirenzThe serum concentration of Estrone sulfate can be decreased when it is combined with Efavirenz.Approved, Investigational
ElafinThe serum concentration of Estrone sulfate can be decreased when it is combined with Elafin.Investigational
ElvitegravirThe serum concentration of Estrone sulfate can be decreased when it is combined with Elvitegravir.Approved
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Estrone sulfate.Approved
EnalaprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Enalapril.Approved, Vet Approved
EnalaprilatThe serum concentration of Estrone sulfate can be decreased when it is combined with Enalaprilat.Approved
EnalkirenThe serum concentration of Estrone sulfate can be decreased when it is combined with Enalkiren.Experimental
EnoxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Enoxacin.Approved
EnzalutamideThe serum concentration of Estrone sulfate can be decreased when it is combined with Enzalutamide.Approved
EpirizoleThe risk or severity of adverse effects can be increased when Epirizole is combined with Estrone sulfate.Approved
EquolThe serum concentration of Estrone sulfate can be increased when it is combined with S Equol.Investigational
ErythromycinThe metabolism of Estrone sulfate can be decreased when combined with Erythromycin.Approved, Vet Approved
Eslicarbazepine acetateThe serum concentration of Estrone sulfate can be decreased when it is combined with Eslicarbazepine acetate.Approved
EstradiolThe serum concentration of Estrone sulfate can be increased when it is combined with Estradiol.Approved, Investigational, Vet Approved
EstriolThe serum concentration of Estrone sulfate can be increased when it is combined with Estriol.Approved, Vet Approved
EstroneThe serum concentration of Estrone sulfate can be increased when it is combined with Estrone.Approved
Etacrynic acidEstrone sulfate may increase the hypokalemic activities of Etacrynic acid.Approved
EtanerceptThe risk or severity of adverse effects can be increased when Etanercept is combined with Estrone sulfate.Approved, Investigational
Ethinyl EstradiolThe serum concentration of Estrone sulfate can be increased when it is combined with Ethinyl Estradiol.Approved
Ethyl biscoumacetateEstrone sulfate may decrease the anticoagulant activities of Ethyl biscoumacetate.Withdrawn
EtodolacThe risk or severity of adverse effects can be increased when Etodolac is combined with Estrone sulfate.Approved, Investigational, Vet Approved
EtofenamateThe risk or severity of adverse effects can be increased when Etofenamate is combined with Estrone sulfate.Approved
EtoricoxibThe risk or severity of adverse effects can be increased when Etoricoxib is combined with Estrone sulfate.Approved, Investigational
EtravirineThe serum concentration of Estrone sulfate can be decreased when it is combined with Etravirine.Approved
ExenatideThe serum concentration of Estrone sulfate can be decreased when it is combined with Exenatide.Approved, Investigational
FaldaprevirThe serum concentration of Estrone sulfate can be decreased when it is combined with Bi201335.Investigational
FelbamateThe serum concentration of Estrone sulfate can be decreased when it is combined with Felbamate.Approved
FenbufenThe risk or severity of adverse effects can be increased when Fenbufen is combined with Estrone sulfate.Approved
FenoprofenThe risk or severity of adverse effects can be increased when Fenoprofen is combined with Estrone sulfate.Approved
FleroxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Fleroxacin.Approved
FlibanserinThe serum concentration of Flibanserin can be increased when it is combined with Estrone sulfate.Approved
FloctafenineThe risk or severity of adverse effects can be increased when Floctafenine is combined with Estrone sulfate.Approved, Withdrawn
FluconazoleThe metabolism of Estrone sulfate can be decreased when combined with Fluconazole.Approved
FluindioneEstrone sulfate may decrease the anticoagulant activities of Fluindione.Investigational
FlumequineThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Flumequine.Withdrawn
FluoxymesteroneEstrone sulfate may increase the fluid retaining activities of Fluoxymesterone.Approved, Illicit
FlurbiprofenThe risk or severity of adverse effects can be increased when Flurbiprofen is combined with Estrone sulfate.Approved, Investigational
FluvoxamineThe metabolism of Estrone sulfate can be decreased when combined with Fluvoxamine.Approved, Investigational
FosamprenavirThe serum concentration of Estrone sulfate can be decreased when it is combined with Fosamprenavir.Approved
FosaprepitantThe serum concentration of Estrone sulfate can be increased when it is combined with Fosaprepitant.Approved
FosinoprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Fosinopril.Approved
FosphenytoinThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Fosphenytoin.Approved
FurosemideEstrone sulfate may increase the hypokalemic activities of Furosemide.Approved, Vet Approved
Fusidic AcidThe serum concentration of Estrone sulfate can be increased when it is combined with Fusidic Acid.Approved
G17DTThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with G17DT.Investigational
GabexateThe serum concentration of Estrone sulfate can be decreased when it is combined with Gabexate.Investigational
GalantamineThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Galantamine.Approved
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Gallamine Triethiodide.Approved
GatifloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Gatifloxacin.Approved, Investigational
GeldanamycinThe serum concentration of Estrone sulfate can be decreased when it is combined with Geldanamycin.Experimental
GemifloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Gemifloxacin.Approved, Investigational
GenisteinThe serum concentration of Estrone sulfate can be increased when it is combined with Genistein.Investigational
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Ginkgo biloba.Approved, Nutraceutical
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Estrone sulfate.Withdrawn
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Estrone sulfate.Approved
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Estrone sulfate.Approved
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Estrone sulfate.Approved
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Estrone sulfate.Approved
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Estrone sulfate.Approved
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Estrone sulfate.Approved
GM6001The serum concentration of Estrone sulfate can be decreased when it is combined with GM6001.Experimental
GrepafloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Grepafloxacin.Withdrawn
GriseofulvinThe metabolism of Estrone sulfate can be increased when combined with Griseofulvin.Approved, Vet Approved
GusperimusThe therapeutic efficacy of Gusperimus can be decreased when used in combination with Estrone sulfate.Investigational
HexestrolThe serum concentration of Estrone sulfate can be increased when it is combined with Hexestrol.Withdrawn
HexobarbitalThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Hexobarbital.Approved
HigenamineThe risk or severity of adverse effects can be increased when Higenamine is combined with Estrone sulfate.Investigational
Huperzine AThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Huperzine A.Investigational
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Estrone sulfate.Approved, Investigational
HydrochlorothiazideEstrone sulfate may increase the hypokalemic activities of Hydrochlorothiazide.Approved, Vet Approved
HydroflumethiazideEstrone sulfate may increase the hypokalemic activities of Hydroflumethiazide.Approved
IbuprofenThe risk or severity of adverse effects can be increased when Ibuprofen is combined with Estrone sulfate.Approved
IbuproxamThe risk or severity of adverse effects can be increased when Ibuproxam is combined with Estrone sulfate.Withdrawn
IcatibantThe risk or severity of adverse effects can be increased when Icatibant is combined with Estrone sulfate.Approved
IdelalisibThe serum concentration of Estrone sulfate can be increased when it is combined with Idelalisib.Approved
ImatinibThe metabolism of Estrone sulfate can be decreased when combined with Imatinib.Approved
ImidaprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Imidapril.Investigational
IndacaterolIndacaterol may increase the hypokalemic activities of Estrone sulfate.Approved
IndapamideEstrone sulfate may increase the hypokalemic activities of Indapamide.Approved
IndinavirThe metabolism of Estrone sulfate can be decreased when combined with Indinavir.Approved
IndomethacinThe risk or severity of adverse effects can be increased when Indomethacin is combined with Estrone sulfate.Approved, Investigational
IndoprofenThe risk or severity of adverse effects can be increased when Indoprofen is combined with Estrone sulfate.Withdrawn
INGN 201The risk or severity of adverse effects can be increased when Estrone sulfate is combined with INGN 201.Investigational
INGN 225The risk or severity of adverse effects can be increased when Estrone sulfate is combined with INGN 225.Investigational
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Estrone sulfate.Approved
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Estrone sulfate.Approved
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Estrone sulfate.Approved
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Estrone sulfate.Approved
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Estrone sulfate.Approved
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Estrone sulfate.Approved
IsavuconazoniumThe metabolism of Estrone sulfate can be decreased when combined with Isavuconazonium.Approved, Investigational
IsoflurophateThe serum concentration of Estrone sulfate can be decreased when it is combined with Isoflurophate.Approved, Withdrawn
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Estrone sulfate.Approved
IsotretinoinThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Isotretinoin.Approved
IsoxicamThe risk or severity of adverse effects can be increased when Isoxicam is combined with Estrone sulfate.Withdrawn
IsradipineThe metabolism of Estrone sulfate can be decreased when combined with Isradipine.Approved
ItraconazoleThe metabolism of Estrone sulfate can be decreased when combined with Itraconazole.Approved, Investigational
IvacaftorThe serum concentration of Estrone sulfate can be increased when it is combined with Ivacaftor.Approved
IxazomibThe serum concentration of Estrone sulfate can be decreased when it is combined with Ixazomib.Approved
KebuzoneThe risk or severity of adverse effects can be increased when Kebuzone is combined with Estrone sulfate.Experimental
KetoconazoleThe metabolism of Estrone sulfate can be decreased when combined with Ketoconazole.Approved, Investigational
KetoprofenThe risk or severity of adverse effects can be increased when Ketoprofen is combined with Estrone sulfate.Approved, Vet Approved
KetorolacThe risk or severity of adverse effects can be increased when Ketorolac is combined with Estrone sulfate.Approved
LamotrigineThe serum concentration of Lamotrigine can be decreased when it is combined with Estrone sulfate.Approved, Investigational
LeflunomideThe risk or severity of adverse effects can be increased when Leflunomide is combined with Estrone sulfate.Approved, Investigational
LepirudinThe serum concentration of Estrone sulfate can be decreased when it is combined with Lepirudin.Approved
LevofloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Levofloxacin.Approved, Investigational
LidocaineThe metabolism of Estrone sulfate can be decreased when combined with Lidocaine.Approved, Vet Approved
LinagliptinThe serum concentration of Estrone sulfate can be decreased when it is combined with Linagliptin.Approved
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Estrone sulfate.Approved
LisinoprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Lisinopril.Approved, Investigational
LisofyllineThe risk or severity of adverse effects can be increased when Lisofylline is combined with Estrone sulfate.Investigational
LomefloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Lomefloxacin.Approved
LopinavirThe metabolism of Estrone sulfate can be decreased when combined with Lopinavir.Approved
LornoxicamThe risk or severity of adverse effects can be increased when Lornoxicam is combined with Estrone sulfate.Approved
LovastatinThe metabolism of Estrone sulfate can be decreased when combined with Lovastatin.Approved, Investigational
LoxoprofenThe risk or severity of adverse effects can be increased when Loxoprofen is combined with Estrone sulfate.Approved
LuliconazoleThe serum concentration of Estrone sulfate can be increased when it is combined with Luliconazole.Approved
LumacaftorThe serum concentration of Estrone sulfate can be decreased when it is combined with Lumacaftor.Approved
LumiracoxibThe risk or severity of adverse effects can be increased when Lumiracoxib is combined with Estrone sulfate.Approved, Investigational
MagaldrateThe bioavailability of Estrone sulfate can be decreased when combined with Magaldrate.Withdrawn
Magnesium carbonateThe bioavailability of Estrone sulfate can be decreased when combined with Magnesium carbonate.Approved
Magnesium HydroxideThe bioavailability of Estrone sulfate can be decreased when combined with Magnesium hydroxide.Approved
Magnesium oxideThe bioavailability of Estrone sulfate can be decreased when combined with Magnesium oxide.Approved
Magnesium salicylateThe risk or severity of adverse effects can be increased when Magnesium salicylate is combined with Estrone sulfate.Approved
Magnesium TrisilicateThe bioavailability of Estrone sulfate can be decreased when combined with Magnesium Trisilicate.Approved
MalathionThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Malathion.Approved, Investigational
MasoprocolThe risk or severity of adverse effects can be increased when Masoprocol is combined with Estrone sulfate.Approved
Meclofenamic acidThe risk or severity of adverse effects can be increased when Meclofenamic acid is combined with Estrone sulfate.Approved, Vet Approved
Mefenamic acidThe risk or severity of adverse effects can be increased when Mefenamic acid is combined with Estrone sulfate.Approved
MefloquineThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Mefloquine.Approved
MeloxicamThe risk or severity of adverse effects can be increased when Meloxicam is combined with Estrone sulfate.Approved, Vet Approved
MemantineThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Memantine.Approved, Investigational
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Estrone sulfate.Approved
MestranolThe serum concentration of Estrone sulfate can be increased when it is combined with Mestranol.Approved
MetamizoleThe risk or severity of adverse effects can be increased when Metamizole is combined with Estrone sulfate.Withdrawn
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Estrone sulfate.Approved
MethallenestrilThe serum concentration of Estrone sulfate can be increased when it is combined with Methallenestril.Experimental
Methanesulfonyl FluorideThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Methanesulfonyl Fluoride.Investigational
MethohexitalThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Methohexital.Approved
MethyclothiazideEstrone sulfate may increase the hypokalemic activities of Methyclothiazide.Approved
MethylphenobarbitalThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Methylphenobarbital.Approved
MethyltestosteroneEstrone sulfate may increase the fluid retaining activities of Methyltestosterone.Approved
MetolazoneEstrone sulfate may increase the hypokalemic activities of Metolazone.Approved
MetreleptinThe serum concentration of Estrone sulfate can be decreased when it is combined with Metreleptin.Approved
MexiletineThe metabolism of Estrone sulfate can be decreased when combined with Mexiletine.Approved
MifepristoneThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Mifepristone.Approved, Investigational
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Estrone sulfate.Approved
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Estrone sulfate.Approved
MinaprineThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Minaprine.Approved
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Estrone sulfate.Approved, Investigational
MitotaneThe serum concentration of Estrone sulfate can be decreased when it is combined with Mitotane.Approved
MivacuriumMivacurium may increase the adverse neuromuscular activities of Estrone sulfate.Approved
MizoribineThe risk or severity of adverse effects can be increased when Mizoribine is combined with Estrone sulfate.Investigational
ModafinilThe serum concentration of Estrone sulfate can be decreased when it is combined with Modafinil.Approved, Investigational
MoexiprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Moexipril.Approved
MoxifloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Moxifloxacin.Approved, Investigational
Mycophenolate mofetilThe risk or severity of adverse effects can be increased when Mycophenolate mofetil is combined with Estrone sulfate.Approved, Investigational
Mycophenolic acidThe serum concentration of Estrone sulfate can be decreased when it is combined with Mycophenolic acid.Approved
N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-ProlineThe serum concentration of Estrone sulfate can be decreased when it is combined with N-(3-Propylcarbamoyloxirane-2-Carbonyl)-Isoleucyl-Proline.Experimental
NabumetoneThe risk or severity of adverse effects can be increased when Nabumetone is combined with Estrone sulfate.Approved
NafamostatThe serum concentration of Estrone sulfate can be decreased when it is combined with Nafamostat.Approved, Investigational
NafcillinThe metabolism of Estrone sulfate can be increased when combined with Nafcillin.Approved
NaftifineThe risk or severity of adverse effects can be increased when Naftifine is combined with Estrone sulfate.Approved
Nalidixic AcidThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Nalidixic Acid.Approved
NaproxenThe risk or severity of adverse effects can be increased when Naproxen is combined with Estrone sulfate.Approved, Vet Approved
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Estrone sulfate.Approved, Investigational
NefazodoneThe metabolism of Estrone sulfate can be decreased when combined with Nefazodone.Approved, Withdrawn
NelfinavirThe metabolism of Estrone sulfate can be decreased when combined with Nelfinavir.Approved
NeostigmineThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Neostigmine.Approved, Vet Approved
NepafenacThe risk or severity of adverse effects can be increased when Nepafenac is combined with Estrone sulfate.Approved
NetupitantThe serum concentration of Estrone sulfate can be increased when it is combined with Netupitant.Approved
NevirapineThe serum concentration of Estrone sulfate can be decreased when it is combined with Nevirapine.Approved
NicorandilThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Nicorandil.Approved
Niflumic AcidThe risk or severity of adverse effects can be increased when Niflumic Acid is combined with Estrone sulfate.Approved
NilotinibThe metabolism of Estrone sulfate can be decreased when combined with Nilotinib.Approved, Investigational
NimesulideThe risk or severity of adverse effects can be increased when Nimesulide is combined with Estrone sulfate.Approved, Withdrawn
NitroaspirinThe serum concentration of Estrone sulfate can be decreased when it is combined with Nitroaspirin.Investigational
NorfloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Norfloxacin.Approved
OfloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Ofloxacin.Approved
OlaparibThe metabolism of Estrone sulfate can be decreased when combined with Olaparib.Approved
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Estrone sulfate.Approved
OlsalazineThe risk or severity of adverse effects can be increased when Olsalazine is combined with Estrone sulfate.Approved
OmapatrilatThe serum concentration of Estrone sulfate can be decreased when it is combined with Omapatrilat.Investigational
OsimertinibThe serum concentration of Estrone sulfate can be increased when it is combined with Osimertinib.Approved
OxandroloneEstrone sulfate may increase the fluid retaining activities of Oxandrolone.Approved, Investigational
OxaprozinThe risk or severity of adverse effects can be increased when Oxaprozin is combined with Estrone sulfate.Approved
OxcarbazepineThe serum concentration of Estrone sulfate can be decreased when it is combined with Oxcarbazepine.Approved
OxymetholoneEstrone sulfate may increase the fluid retaining activities of Oxymetholone.Approved, Illicit
OxyphenbutazoneThe risk or severity of adverse effects can be increased when Oxyphenbutazone is combined with Estrone sulfate.Withdrawn
PalbociclibThe serum concentration of Estrone sulfate can be increased when it is combined with Palbociclib.Approved
ParecoxibThe risk or severity of adverse effects can be increased when Parecoxib is combined with Estrone sulfate.Approved
PazufloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Pazufloxacin.Investigational
PefloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Pefloxacin.Approved
Peginterferon alfa-2bThe serum concentration of Estrone sulfate can be increased when it is combined with Peginterferon alfa-2b.Approved
PentobarbitalThe metabolism of Estrone sulfate can be increased when combined with Pentobarbital.Approved, Vet Approved
PerindoprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Perindopril.Approved
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Estrone sulfate.Approved, Withdrawn
PhenindioneEstrone sulfate may decrease the anticoagulant activities of Phenindione.Approved
PhenobarbitalThe metabolism of Estrone sulfate can be increased when combined with Phenobarbital.Approved
PhenprocoumonEstrone sulfate may decrease the anticoagulant activities of Phenprocoumon.Approved
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Estrone sulfate.Approved
PhenylbutazoneThe risk or severity of adverse effects can be increased when Phenylbutazone is combined with Estrone sulfate.Approved, Vet Approved
Phenylbutyric acidThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Estrone sulfate.Approved, Investigational
PhenytoinThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Phenytoin.Approved, Vet Approved
PhosphoramidonThe serum concentration of Estrone sulfate can be decreased when it is combined with Phosphoramidon.Experimental
PhysostigmineThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Physostigmine.Approved
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Estrone sulfate.Approved, Investigational
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Estrone sulfate.Approved, Investigational
PiretanideEstrone sulfate may increase the hypokalemic activities of Piretanide.Experimental
PirfenidoneThe risk or severity of adverse effects can be increased when Pirfenidone is combined with Estrone sulfate.Investigational
PiroxicamThe risk or severity of adverse effects can be increased when Piroxicam is combined with Estrone sulfate.Approved, Investigational
PolythiazideEstrone sulfate may increase the hypokalemic activities of Polythiazide.Approved
PosaconazoleThe metabolism of Estrone sulfate can be decreased when combined with Posaconazole.Approved, Investigational, Vet Approved
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Estrone sulfate.Approved, Investigational
PrimidoneThe metabolism of Estrone sulfate can be increased when combined with Primidone.Approved, Vet Approved
PrinomastatThe serum concentration of Estrone sulfate can be decreased when it is combined with Prinomastat.Investigational
PromestrieneThe serum concentration of Estrone sulfate can be increased when it is combined with Promestriene.Investigational
PropacetamolThe risk or severity of adverse effects can be increased when Propacetamol is combined with Estrone sulfate.Approved
PrucaloprideThe serum concentration of Estrone sulfate can be decreased when it is combined with Prucalopride.Approved
PrulifloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Prulifloxacin.Investigational
PTC299The risk or severity of adverse effects can be increased when PTC299 is combined with Estrone sulfate.Investigational
PyridostigmineThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Pyridostigmine.Approved
QuinaprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Quinapril.Approved, Investigational
QuinestrolThe serum concentration of Estrone sulfate can be increased when it is combined with Quinestrol.Approved
QuinethazoneEstrone sulfate may increase the hypokalemic activities of Quinethazone.Approved
RacecadotrilThe serum concentration of Estrone sulfate can be decreased when it is combined with Racecadotril.Investigational
RamiprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Ramipril.Approved
RanolazineThe metabolism of Estrone sulfate can be decreased when combined with Ranolazine.Approved, Investigational
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Estrone sulfate.Withdrawn
RemikirenThe serum concentration of Estrone sulfate can be decreased when it is combined with Remikiren.Approved
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Estrone sulfate.Approved, Investigational
ResveratrolThe risk or severity of adverse effects can be increased when Resveratrol is combined with Estrone sulfate.Experimental, Investigational
RifabutinThe metabolism of Estrone sulfate can be increased when combined with Rifabutin.Approved
RifampicinThe metabolism of Estrone sulfate can be increased when combined with Rifampicin.Approved
RifapentineThe metabolism of Estrone sulfate can be increased when combined with Rifapentine.Approved
RindopepimutThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with CDX-110.Investigational
RitonavirThe metabolism of Estrone sulfate can be decreased when combined with Ritonavir.Approved, Investigational
RivaroxabanThe serum concentration of Estrone sulfate can be decreased when it is combined with Rivaroxaban.Approved
RivastigmineThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rivastigmine.Approved, Investigational
RofecoxibThe risk or severity of adverse effects can be increased when Rofecoxib is combined with Estrone sulfate.Investigational, Withdrawn
RopiniroleThe metabolism of Estrone sulfate can be decreased when combined with Ropinirole.Approved, Investigational
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Estrone sulfate.Approved, Investigational
RosoxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Rosoxacin.Approved
SalicylamideThe risk or severity of adverse effects can be increased when Salicylamide is combined with Estrone sulfate.Approved
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Estrone sulfate.Approved, Vet Approved
SalsalateThe risk or severity of adverse effects can be increased when Salsalate is combined with Estrone sulfate.Approved
SaquinavirThe metabolism of Estrone sulfate can be decreased when combined with Saquinavir.Approved, Investigational
SaxagliptinThe serum concentration of Estrone sulfate can be decreased when it is combined with Saxagliptin.Approved
SecobarbitalThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Secobarbital.Approved, Vet Approved
SecoisolariciresinolThe serum concentration of Estrone sulfate can be increased when it is combined with Secoisolariciresinol.Investigational
SelegilineThe serum concentration of Selegiline can be increased when it is combined with Estrone sulfate.Approved, Investigational, Vet Approved
SildenafilThe metabolism of Estrone sulfate can be decreased when combined with Sildenafil.Approved, Investigational
SiltuximabThe serum concentration of Estrone sulfate can be decreased when it is combined with Siltuximab.Approved
SimeprevirThe serum concentration of Estrone sulfate can be increased when it is combined with Simeprevir.Approved
SitagliptinThe serum concentration of Estrone sulfate can be decreased when it is combined with Sitagliptin.Approved, Investigational
SparfloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Sparfloxacin.Approved
SpiraprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Spirapril.Approved
SRP 299The risk or severity of adverse effects can be increased when Estrone sulfate is combined with SRP 299.Investigational
SRT501The risk or severity of adverse effects can be increased when SRT501 is combined with Estrone sulfate.Investigational
St. John's WortThe serum concentration of Estrone sulfate can be decreased when it is combined with St. John's Wort.Nutraceutical
StanozololEstrone sulfate may increase the fluid retaining activities of Stanozolol.Approved, Vet Approved
StiripentolThe serum concentration of Estrone sulfate can be increased when it is combined with Stiripentol.Approved
SulfasalazineThe risk or severity of adverse effects can be increased when Sulfasalazine is combined with Estrone sulfate.Approved
SulfisoxazoleThe metabolism of Estrone sulfate can be decreased when combined with Sulfisoxazole.Approved, Vet Approved
SulindacThe risk or severity of adverse effects can be increased when Sulindac is combined with Estrone sulfate.Approved
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Estrone sulfate.Approved, Investigational
SuprofenThe risk or severity of adverse effects can be increased when Suprofen is combined with Estrone sulfate.Approved, Withdrawn
Synthetic Conjugated Estrogens, AThe serum concentration of Estrone sulfate can be increased when it is combined with Synthetic Conjugated Estrogens, A.Approved
Synthetic Conjugated Estrogens, BThe serum concentration of Estrone sulfate can be increased when it is combined with Synthetic Conjugated Estrogens, B.Approved
TacrineThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Tacrine.Withdrawn
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Estrone sulfate.Withdrawn
TelithromycinThe metabolism of Estrone sulfate can be decreased when combined with Telithromycin.Approved
TemafloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Temafloxacin.Withdrawn
TemocaprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Temocapril.Experimental, Investigational
Tenofovir disoproxilThe metabolism of Estrone sulfate can be decreased when combined with Tenofovir.Approved, Investigational
TenoxicamThe risk or severity of adverse effects can be increased when Tenoxicam is combined with Estrone sulfate.Approved
TeriflunomideThe serum concentration of Estrone sulfate can be decreased when it is combined with Teriflunomide.Approved
TestosteroneEstrone sulfate may increase the fluid retaining activities of Testosterone.Approved, Investigational
ThalidomideEstrone sulfate may increase the thrombogenic activities of Thalidomide.Approved, Investigational, Withdrawn
TheophyllineThe metabolism of Estrone sulfate can be decreased when combined with Theophylline.Approved
ThiamylalThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Thiamylal.Approved, Vet Approved
ThiopentalThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Thiopental.Approved, Vet Approved
ThiorphanThe serum concentration of Estrone sulfate can be decreased when it is combined with Thiorphan.Experimental
Tiaprofenic acidThe risk or severity of adverse effects can be increased when Tiaprofenic acid is combined with Estrone sulfate.Approved
TiboloneThe serum concentration of Estrone sulfate can be increased when it is combined with Tibolone.Approved
TiclopidineThe metabolism of Estrone sulfate can be decreased when combined with Ticlopidine.Approved
TinoridineThe risk or severity of adverse effects can be increased when Tinoridine is combined with Estrone sulfate.Investigational
TipranavirThe serum concentration of Estrone sulfate can be decreased when it is combined with Tipranavir.Approved, Investigational
TocilizumabThe serum concentration of Estrone sulfate can be decreased when it is combined with Tocilizumab.Approved
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Estrone sulfate.Approved
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Estrone sulfate.Approved
Tolfenamic AcidThe risk or severity of adverse effects can be increased when Tolfenamic Acid is combined with Estrone sulfate.Approved
TolmetinThe risk or severity of adverse effects can be increased when Tolmetin is combined with Estrone sulfate.Approved
TopiramateThe serum concentration of Estrone sulfate can be decreased when it is combined with Topiramate.Approved
TorasemideEstrone sulfate may increase the hypokalemic activities of Torasemide.Approved
TrandolaprilThe serum concentration of Estrone sulfate can be decreased when it is combined with Trandolapril.Approved
Tranexamic AcidEstrone sulfate may increase the thrombogenic activities of Tranexamic Acid.Approved
TranilastThe risk or severity of adverse effects can be increased when Tranilast is combined with Estrone sulfate.Approved, Investigational
TretinoinThe therapeutic efficacy of Estrone sulfate can be decreased when used in combination with Tretinoin.Approved, Investigational, Nutraceutical
TrichlormethiazideEstrone sulfate may increase the hypokalemic activities of Trichlormethiazide.Approved, Vet Approved
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Estrone sulfate.Withdrawn
TrovafloxacinThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Trovafloxacin.Approved, Withdrawn
TubocurarineThe risk or severity of adverse effects can be increased when Estrone sulfate is combined with Tubocurarine.Approved
UbenimexThe serum concentration of Estrone sulfate can be decreased when it is combined with Ubenimex.Experimental
UlinastatinThe serum concentration of Estrone sulfate can be decreased when it is combined with Ulinastatin.Investigational
ValdecoxibThe risk or severity of adverse effects can be increased when Valdecoxib is combined with Estrone sulfate.Investigational, Withdrawn
VemurafenibThe serum concentration of Estrone sulfate can be increased when it is combined with Vemurafenib.Approved
VenlafaxineThe metabolism of Estrone sulfate can be decreased when combined with Venlafaxine.Approved
VerapamilThe metabolism of Estrone sulfate can be decreased when combined with Verapamil.Approved
VildagliptinThe serum concentration of Estrone sulfate can be decreased when it is combined with Vildagliptin.Approved, Investigational
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Estrone sulfate.Approved, Investigational
VoriconazoleThe metabolism of Estrone sulfate can be decreased when combined with Voriconazole.Approved, Investigational
WarfarinEstrone sulfate may increase the anticoagulant activities of Warfarin.Approved
XimelagatranThe serum concentration of Estrone sulfate can be decreased when it is combined with Ximelagatran.Approved, Investigational, Withdrawn
ZaltoprofenThe risk or severity of adverse effects can be increased when Zaltoprofen is combined with Estrone sulfate.Approved
ZileutonThe risk or severity of adverse effects can be increased when Zileuton is combined with Estrone sulfate.Approved, Investigational, Withdrawn
ZiprasidoneThe metabolism of Estrone sulfate can be decreased when combined with Ziprasidone.Approved
ZomepiracThe risk or severity of adverse effects can be increased when Zomepirac is combined with Estrone sulfate.Withdrawn
Food Interactions
  • Take with food to decrease nausea
References
Synthesis ReferenceNot Available
General ReferencesNot Available
External Links
ATC CodesNot Available
AHFS Codes
  • 68:16.04
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Clinical Trials
Clinical Trials Not Available
Pharmacoeconomics
ManufacturersNot Available
PackagersNot Available
Dosage forms
FormRouteStrength
Tablet, film coatedOral
TabletOral.75 mg/1
TabletOral1.5 mg/1
TabletOral3 mg/1
TabletOral0.75 mg
TabletOral1.5 mg
TabletOral3.0 mg
PricesNot Available
PatentsNot Available
Properties
StateSolid
Experimental PropertiesNot Available
Predicted Properties
PropertyValueSource
Water Solubility0.0059 mg/mLALOGPS
logP0.29ALOGPS
logP3.83ChemAxon
logS-4.8ALOGPS
pKa (Strongest Acidic)-1.7ChemAxon
pKa (Strongest Basic)-7.5ChemAxon
Physiological Charge-1ChemAxon
Hydrogen Acceptor Count4ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area80.67 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity89.07 m3·mol-1ChemAxon
Polarizability36.64 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9974
Blood Brain Barrier+0.935
Caco-2 permeable-0.8343
P-glycoprotein substrateNon-substrate0.5376
P-glycoprotein inhibitor INon-inhibitor0.5591
P-glycoprotein inhibitor IINon-inhibitor0.9751
Renal organic cation transporterNon-inhibitor0.8407
CYP450 2C9 substrateNon-substrate0.7526
CYP450 2D6 substrateNon-substrate0.8214
CYP450 3A4 substrateSubstrate0.6275
CYP450 1A2 substrateNon-inhibitor0.9046
CYP450 2C9 inhibitorNon-inhibitor0.9071
CYP450 2D6 inhibitorNon-inhibitor0.923
CYP450 2C19 inhibitorNon-inhibitor0.9026
CYP450 3A4 inhibitorNon-inhibitor0.9421
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.8808
Ames testNon AMES toxic0.5621
CarcinogenicityCarcinogens 0.5507
BiodegradationNot ready biodegradable0.9558
Rat acute toxicity2.2402 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Strong inhibitor0.5746
hERG inhibition (predictor II)Inhibitor0.8077
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as sulfated steroids. These are sterol lipids containing a sulfate group attached to the steroid skeleton.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassSulfated steroids
Direct ParentSulfated steroids
Alternative ParentsEstrane steroids / 17-oxosteroids / Phenanthrenes and derivatives / Tetralins / Arylsulfates / Sulfuric acid monoesters / Ketones / Organic oxides / Hydrocarbon derivatives
SubstituentsSulfated steroid skeleton / Estrane-skeleton / 17-oxosteroid / Oxosteroid / Phenanthrene / Arylsulfate / Tetralin / Benzenoid / Sulfuric acid ester / Sulfuric acid monoester
Molecular FrameworkAromatic homopolycyclic compounds
External Descriptorssteroid sulfate, 17-oxo steroid (CHEBI:17474 ) / sulfates, C18 steroids (estrogens) and derivatives, Estrogens (C02538 ) / C18 steroids (estrogens) and derivatives (LMST02010043 )

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. The steroid hormones and their receptors are involved in the regulation of eukaryotic gene expression and affect cellular proliferation and differentiation in target tissues. Ligand-dependent nuclear transactivation involves either direct homodimer binding to a palindromic estrogen response element (ERE) sequence or association with other DNA-binding transcription fact...
Gene Name:
ESR1
Uniprot ID:
P03372
Uniprot Name:
Estrogen receptor
Molecular Weight:
66215.45 Da
References
  1. Brama M, Gnessi L, Basciani S, Cerulli N, Politi L, Spera G, Mariani S, Cherubini S, Scotto d'Abusco A, Scandurra R, Migliaccio S: Cadmium induces mitogenic signaling in breast cancer cell by an ERalpha-dependent mechanism. Mol Cell Endocrinol. 2007 Jan 29;264(1-2):102-8. Epub 2006 Nov 27. [PubMed:17125913 ]
  2. Lehnes K, Winder AD, Alfonso C, Kasid N, Simoneaux M, Summe H, Morgan E, Iann MC, Duncan J, Eagan M, Tavaluc R, Evans CH Jr, Russell R, Wang A, Hu F, Stoica A: The effect of estradiol on in vivo tumorigenesis is modulated by the human epidermal growth factor receptor 2/phosphatidylinositol 3-kinase/Akt1 pathway. Endocrinology. 2007 Mar;148(3):1171-80. Epub 2006 Nov 30. [PubMed:17138652 ]
  3. Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69. [PubMed:2011412 ]
  4. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Nuclear hormone receptor. Binds estrogens with an affinity similar to that of ESR1, and activates expression of reporter genes containing estrogen response elements (ERE) in an estrogen-dependent manner (PubMed:20074560). Isoform beta-cx lacks ligand binding ability and has no or only very low ere binding activity resulting in the loss of ligand-dependent transactivation ability. DNA-binding by...
Gene Name:
ESR2
Uniprot ID:
Q92731
Uniprot Name:
Estrogen receptor beta
Molecular Weight:
59215.765 Da
References
  1. Vijayanathan V, Greenfield NJ, Thomas TJ, Ivanova MM, Tyulmenkov VV, Klinge CM, Gallo MA, Thomas T: Effects of estradiol and 4-hydroxytamoxifen on the conformation, thermal stability, and DNA recognition of estrogen receptor beta. Biochem Cell Biol. 2007 Feb;85(1):1-10. [PubMed:17464340 ]
  2. Sasson S: Equilibrium binding analysis of estrogen agonists and antagonists: relation to the activation of the estrogen receptor. Pathol Biol (Paris). 1991 Jan;39(1):59-69. [PubMed:2011412 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. Most active in catalyzing 2-hydroxylation. Caffeine is metabolized primarily by cytochrome CYP1A2 in the liver through an initial N...
Gene Name:
CYP1A2
Uniprot ID:
P05177
Uniprot Name:
Cytochrome P450 1A2
Molecular Weight:
58293.76 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. [PubMed:12865317 ]
  3. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Uniprot Name:
Cytochrome P450 3A4
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
  2. Lee AJ, Cai MX, Thomas PE, Conney AH, Zhu BT: Characterization of the oxidative metabolites of 17beta-estradiol and estrone formed by 15 selectively expressed human cytochrome p450 isoforms. Endocrinology. 2003 Aug;144(8):3382-98. [PubMed:12865317 ]
  3. Williams ET, Leyk M, Wrighton SA, Davies PJ, Loose DS, Shipley GL, Strobel HW: Estrogen regulation of the cytochrome P450 3A subfamily in humans. J Pharmacol Exp Ther. 2004 Nov;311(2):728-35. Epub 2004 Jul 28. [PubMed:15282264 ]
  4. Drug Interactions: Cytochrome P450 Drug Interaction Table [Link]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inducer
General Function:
Steroid hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It oxidizes a variety of structurally unrelated compounds, including steroids, fatty acids, and xenobiotics. This enzyme contributes to the wide pharmacokinetics variability of the metabolism of drugs such as S-warfarin, diclofenac, phenyto...
Gene Name:
CYP2C9
Uniprot ID:
P11712
Uniprot Name:
Cytochrome P450 2C9
Molecular Weight:
55627.365 Da
References
  1. Egnell AC, Eriksson C, Albertson N, Houston B, Boyer S: Generation and evaluation of a CYP2C9 heteroactivation pharmacophore. J Pharmacol Exp Ther. 2003 Dec;307(3):878-87. Epub 2003 Oct 13. [PubMed:14557374 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Androgen binding
Specific Function:
Functions as an androgen transport protein, but may also be involved in receptor mediated processes. Each dimer binds one molecule of steroid. Specific for 5-alpha-dihydrotestosterone, testosterone, and 17-beta-estradiol. Regulates the plasma metabolic clearance rate of steroid hormones by controlling their plasma concentration.
Gene Name:
SHBG
Uniprot ID:
P04278
Uniprot Name:
Sex hormone-binding globulin
Molecular Weight:
43778.755 Da
References
  1. Campusano M C, Brusco G F, Campino J C, Rodriguez P L, Arteaga U E: [Assessment of androgenic decline in the elderly]. Rev Med Chil. 2006 Sep;134(9):1123-8. Epub 2006 Dec 12. [PubMed:17171213 ]
  2. Kuba R, Pohanka M, Zakopcan J, Novotna I, Rektor I: Sexual dysfunctions and blood hormonal profile in men with focal epilepsy. Epilepsia. 2006 Dec;47(12):2135-40. [PubMed:17201714 ]
  3. Bendlova B, Zavadilova J, Vankova M, Vejrazkova D, Lukasova P, Vcelak J, Hill M, Cibula D, Vondra K, Starka L, Vrbikova J: Role of D327N sex hormone-binding globulin gene polymorphism in the pathogenesis of polycystic ovary syndrome. J Steroid Biochem Mol Biol. 2007 Apr;104(1-2):68-74. Epub 2007 Jan 26. [PubMed:17258903 ]
  4. Sablik Z, Samborska-Sablik A, Bolinska-Soltysiak H, Goch JH, Kula K: [Hyperandrogenism as a risk factor of coronary artery disease in young women]. Pol Arch Med Wewn. 2006 Feb;115(2):118-24. [PubMed:17274467 ]
  5. Mohamad MJ, Mohammad MA, Karayyem M, Hairi A, Hader AA: Serum levels of sex hormones in men with acute myocardial infarction. Neuro Endocrinol Lett. 2007 Apr;28(2):182-6. [PubMed:17435665 ]
  6. O'Connell MB: Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol. 1995 Sep;35(9 Suppl):18S-24S. [PubMed:8530713 ]
  7. Pardridge WM: Serum bioavailability of sex steroid hormones. Clin Endocrinol Metab. 1986 May;15(2):259-78. [PubMed:3521955 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
General Function:
Toxic substance binding
Specific Function:
Serum albumin, the main protein of plasma, has a good binding capacity for water, Ca(2+), Na(+), K(+), fatty acids, hormones, bilirubin and drugs. Its main function is the regulation of the colloidal osmotic pressure of blood. Major zinc transporter in plasma, typically binds about 80% of all plasma zinc.
Gene Name:
ALB
Uniprot ID:
P02768
Uniprot Name:
Serum albumin
Molecular Weight:
69365.94 Da
References
  1. O'Connell MB: Pharmacokinetic and pharmacologic variation between different estrogen products. J Clin Pharmacol. 1995 Sep;35(9 Suppl):18S-24S. [PubMed:8530713 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Secondary active organic cation transmembrane transporter activity
Specific Function:
Translocates a broad array of organic cations with various structures and molecular weights including the model compounds 1-methyl-4-phenylpyridinium (MPP), tetraethylammonium (TEA), N-1-methylnicotinamide (NMN), 4-(4-(dimethylamino)styryl)-N-methylpyridinium (ASP), the endogenous compounds choline, guanidine, histamine, epinephrine, adrenaline, noradrenaline and dopamine, and the drugs quinine...
Gene Name:
SLC22A1
Uniprot ID:
O15245
Uniprot Name:
Solute carrier family 22 member 1
Molecular Weight:
61153.345 Da
References
  1. Hayer-Zillgen M, Bruss M, Bonisch H: Expression and pharmacological profile of the human organic cation transporters hOCT1, hOCT2 and hOCT3. Br J Pharmacol. 2002 Jul;136(6):829-36. [PubMed:12110607 ]
  2. Wu X, Kekuda R, Huang W, Fei YJ, Leibach FH, Chen J, Conway SJ, Ganapathy V: Identity of the organic cation transporter OCT3 as the extraneuronal monoamine transporter (uptake2) and evidence for the expression of the transporter in the brain. J Biol Chem. 1998 Dec 4;273(49):32776-86. [PubMed:9830022 ]
Drug created on September 07, 2007 15:12 / Updated on June 23, 2017 10:14